Biotech Penny Stocks on the Move: TSOI, CYDY, ATRX, NWBO
Biotech stocks were some of the biggest winners at the height of the pandemic amid the investment opportunity created by strong COVID-19 vaccine demand. However, as the pandemic faded away and people learned to live with the virus, concerns around inflation, politics, and the economy took center stage, triggering a steep selloff in the sector.
After a downward slope in 2021 and 2022, biotech stocks are once again coming back to life as investors take note of their depressed valuation. Biotech penny stocks are some of the hottest prospects presenting exciting investment opportunities for investors eyeing exposure to the next big thing in vaccines and drugs.
TSOI, CYDY, ATRX, and NWBO are some of the biotech penny stocks at the center of attention thanks to their strong drug candidate pipelines that affirm long-term prospects
Therapeutic Solutions International Robust ARDS an Aortic Aneurysm Pipeline
Therapeutic Solutions International (OTC:TSOI) is one biotech penny stock showing signs of breaking out, supported by a string of positive underlying fundamentals. Top on the charts is the company filling for clinical trial applications with the Food and Drug Administration. The company is looking to use JadiCell adult stem cells to treat acute respiratory distress syndrome (ARDS).
The ARDS is characterized by lung injury that causes fluid to leak into spaces between capillaries. Fluid accumulation in the spaces often leads to further problems, including decreased lung capacity to move oxygen to the body. Accelerating ARDS programs positions the company to tap into a greater market than COVID-19-induced ARDS.
In addition to pursuing treatment for acute respiratory distress syndrome, Therapeutic Solutions International has also formed a spinoff company that will expand its footprint into treating aortic aneurysms using stem cells. The unit has already started performing Investigational New Drug studies and plans to file with the FDA before the end of the year.
VasoSome Vascular is the new unit that will focus on utilizing stem cell exosomes. According to Therapeutic Solutions International Chief Medical Officer James Veltmeyer, the field of aortic aneurysms is wide open for the application of regenerative medicines.
By leveraging a regenerative medicine base, Therapeutic Solutions International should be able to generate new companies across various areas of biology crucial to advancing patient treatments and developing shareholder value.
In addition, Therapeutic Solutions International has hit yet another significant milestone on its spinoff company Res Nova Bio achieving successful delivery of a cancer-killing virus for breast cancer. The unit was able to achieve shrinkage of the tumor without induction of any side effects.
While still working on the FDA-approved ValloVax endothelial cell vaccine, the spinoff proved that administering viral infected ValloVax to breast cancer could result in regression and generation of immunity. The focus now shifts to the generation of tumor-targeting cell therapies.
Res Nova finding a new cure for breast cancer would be a major milestone, given that the condition affects millions of people worldwide. In addition to helping combat one of the deadliest conditions, the treatment should generate significant value for the parent company.
Investors should closely monitor Therapeutic Solutions International as it makes strides in the development of treatments for acute respiratory distress syndrome and treatment of aortic aneurysms. Milestones achieved in developing treatments designed to combat breast cancer also affirm the company’s long-term prospects.
CytoDyn Milestone on HIV Treatment with Leronlimab
CytoDyn (OTC:CYDY) is another penny stock with tremendous potential amid its push “to alleviate human suffering and improve patients’ quality of life”. The clinical-stage biotechnology company specializes in the development of treatments for multiple indications. It mostly leverages a novel humanized monoclonal antibody.
The company is currently developing leronlimab, a CCR5 receptor antagonist that can be used for various indications, including NASH and HIV. Leronlimab stands out as a unique humanized monoclonal antibody as it can help prevent HIV from using CCR5 to target healthy cells in the body. Preclinical trials have already shown that the humanized monoclonal antibody blocks calcium channel signaling of the CCR5 receptor.
CytoDyn has in its portfolio a valuable asset in Leronlimab that is showing tremendous potential as a powerful antiviral agent. Its less frequent dosing requirements compared to other drug therapies make it an ideal option for addressing the needs of over 37 million people with HIV.
CytoDyn’s long-term prospects and growth metrics remain intact as it continues to develop leronlimab for the treatment of HIV and other types of cancer.
Adhera Therapeutics Parkinson and Type 1 Diabetes Treatment Milestones
Adhera Therapeutics (OTC:ATRX) is a penny stock company for investors looking to gain exposure to the discovery, development, and commercialization of small-molecule drugs. The company is currently working on the development of MLR 1019 targeting Parkinson’s disease and MLR 1023 for the treatment of type 1 diabetes.
It has already made impressive strides in the development of MLR 10123 with the commencement of a dose-finding study in Type 1 diabetes in partnership with the Alberta Diabetes Institute. Teaming up with Alberta Diabetes Institute is an important milestone as it is one of Canada’s largest standalone research facilities. The institute is a perfect partner for working on developing type 1 diabetes while utilizing MLR 1023, a lyn kinase activator.
Amid the progress made on clinical trials, Adhera Therapeutics is also inching a step closer to uplifting its stock on NASDAQ. Listing on the popular marketplace would mark an important milestone, including increased liquidity. In addition, the company could secure more financing for clinical trials given the airplay it will receive on Nasdaq.
Northwest Biotherapeutics UK Production Approval
Northwest Biotherapeutics (OTC:NWBO) is a biotechnology company making waves in the development of personalized immune therapies for cancer. Headquartered in Bethesda, it develops novel treatments based on DCVax, a platform technology that leverages activated dendritic cells to mobilize patients’ immune systems, therefore, attack cancer more effectively.
Early this year, the company together, Advent BioServices, secured an MIA license from the Medicines and Healthcare Products Regulatory Agency to commercialize and manufacture cell therapy products in the UK.
The MIA is the first of two licenses approved in the UK, which is a culmination of 3 years of work. Consequently, biotechnology will be able to develop cell therapies that can be exported globally while also being able to import immune cells into the UK for the production and release of cell therapy products.
The approval marks an important milestone in the company’s push to gain regulatory approval for its lead product DCVax L.
